Earnings ·
Anika Therapeutics reports Q3 revenue of $30.6M, up 10%, and raises full-year guidance
ANIKAnika Therapeutics, Inc.
Anika Therapeutics reported third-quarter 2026 total revenue of $30.6 million, a 10% increase from the prior year period. Commercial Channel revenue grew 17% to $14.0 million, while OEM Channel revenue rose 5% to $16.6 million. The company raised its full-year 2026 total company revenue growth guidance to 6%-10% and increased adjusted EBITDA margin expectations to 15%-17%. Additionally, Anika secured a new 10-year distribution partnership with Boehringer Ingelheim for Hyvisc, expecting $8 million in payments. The firm also received an FDA 'not approvable' letter for its Hyalofast PMA application but completed enrollment for the Cingal bioequivalence study. Anika Therapeutics designs, develops, and commercializes hyaluronic acid innovations for osteoarthritis pain management and orthopedic regenerative solutions.